such as Viking’s dual GLP-1/GIP receptor agonist VK2735 and Structure Therapeutics' oral GLP-1 receptor agonist, GSBR-1290. Furthermore, despite a re-opening market for IPOs (initial public ...

DNA (deoxyribonucleic acid), the molecular "blueprint" carrying the genetic instructions that influence the growth, ...

Chromatin, the mix of DNA and protein that houses each cell's genome, is more resilient to aging than previously thought, suggests a study published in the Journal of the American Chemical Society by ...

The way the body ages could be more resilient than previously thought, a new study suggests.

Far from being uniform in structure and function ... Interferon-stimulated gene 15 (ISG15), a ubiquitin-like molecule with two ubiquitin fold repeats, contains the same C-terminal sequence ...

This is an RNA molecule generated in the lab that the team first presented in 2023. The researchers from the Institute of Organic Chemistry were able to determine the 3D structure of SAMURI using ...

Yes! I want to get the latest chemistry news from C&EN in my inbox every week. ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly ...

Viking Therapeutics has announced the start of a Phase II clinical trial for VK2735, an oral tablet aimed at treating metabolic disorders, such as obesity. The VENTURE-Oral Dosing Trial is a ...

The recent data from Novo Nordisk’s Phase 3b trials highlighted the potential advantages of Viking’s VK2735. Pantginis emphasizes that VK2735, a dual GLP-1/GIP receptor agonist, may ...

In contrast, Viking Therapeutics' shares experienced modest gains. Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only ...